Authors

• Shumao Ni
• Yingying Yu (ORCID: https://orcid.org/0000-0002-6364-2831)
• Caixia Sun (ORCID: https://orcid.org/0000-0002-7606-1809)
• Jiahui Fan (ORCID: https://orcid.org/0009-0002-0135-6968)
• Liyan Miao (ORCID: https://orcid.org/0000-0001-8481-0630)
• Frank Wu (ORCID: https://orcid.org/0000-0001-9927-739X)
• Lin Li (ORCID: https://orcid.org/0000-0002-8629-1149)
• Zhenwen Yu
• Hua Zhang (ORCID: https://orcid.org/0000-0002-3098-4341)
• Peng Peng (ORCID: https://orcid.org/0009-0002-7993-8001)
• Hui Wang (ORCID: https://orcid.org/0000-0002-2454-3814)
• Sheng Ma (ORCID: https://orcid.org/0009-0000-8037-1474)
• Yujia Zhu
• Zhe-ming Gu
• Xiaofen Sun

Institutions

• Panthera Corporation (US)
• China Pharmaceutical University (CN)
• Soochow University (CN)
• First Affiliated Hospital of Soochow University (CN)

Publication Details

Journal

Drugs in R&D

Published

2024-09-01

DOI

https://doi.org/10.1007/s40268-024-00486-2

Citations

1

Primary Topic

Chronic Myeloid Leukemia Treatments

Type

article

Field-Weighted Citation Impact

0.45